Redwoods Acquisition Quick Ratio (RWODU) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Redwoods Acquisition Corp  (NASDAQ: RWODU)

Redwoods Acquisition's Quick Ratio

RWODU's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 7.69 below Redwoods Acquisition Corp average.

Within Biotechnology & Pharmaceuticals industry 46 other companies have achieved higher Quick Ratio than Redwoods Acquisition in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 101 to 112.

Explain Quick Ratio?
How much Cash & cash equivalents RWODU´s has?
What are RWODU´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RWODU Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 1820.06 % -88.91 % -91.26 % -90.54 % -92.99 %
Y / Y Cash & cash equivalent Change 10.31 % 1667.63 % 11159 % - 897.35 %
Quick Ratio MRQ 7.69 38.59 65.84 - 133.82
RWODU's Total Ranking # 112 # 101 # # 53 # 3920
Seq. Current Liabilities Change 366.69 % 137.8 % 17.33 % 47.46 % -97.3 %
Seq. Cash & cash equivalent Change -7.02 % 39.38 % - - 1389.91 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 47
Healthcare Sector # 215
Overall Market # 594


Quick Ratio Statistics
High Average Low
133.82 14.74 0
(Jun 30 2025)   (Dec 31 2023)




Financial Statements
Redwoods Acquisition's Current Liabilities $ 1 Millions Visit RWODU's Balance sheet
Redwoods Acquisition's Cash & cash equivalent $ 9 Millions Visit RWODU's Balance sheet
Source of RWODU's Sales Visit RWODU's Sales by Geography


Cumulative Redwoods Acquisition's Quick Ratio

RWODU's Quick Ratio for the trailling 12 Months

RWODU Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -63.92 % -90.41 % -54.44 % -51.44 % -44.78 %
Y / Y Cash & cash equivalent TTM Growth 190.61 % 1578.42 % 1570.77 % 898.87 % 808.85 %
Quick Ratio TTM 15.85 48.86 6.21 2.42 1.97
Total Ranking TTM # 28 # 263 # 495 # 637 # 2315
Seq. Current Liabilities TTM Growth 218.78 % -79.86 % -30.43 % -19.21 % -15.29 %
Seq. Cash & cash equivalent TTM Growth 3.39 % 58.35 % 78.5 % -0.56 % 497.14 %

Quick ratio ranking by company, industry and sector >> Back to RWODU Financial Strength Comparisons >> Go to Compare RWODU Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $1.21 millions, cumulative Quick Ratio decreased to 15.85 above the RWODU average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 135 other companies have achieved higher Quick Ratio than Redwoods Acquisition. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2451.

Explain Quick Ratio?
How much Cash & cash equivalents RWODU´s has?
What are RWODU´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 136
Healthcare Sector # 823
Within the Market # 112


trailing twelve months Quick Ratio Statistics
High Average Low
32.57 3.9 0.01
(Mar 31 2026)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Instil Bio Inc   21.08 $ 69.678  Millions$ 3.305  Millions
Solid Biosciences Inc   20.85 $ 595.984  Millions$ 28.584  Millions
Relay Therapeutics Inc   17.93 $ 910.934  Millions$ 50.804  Millions
Maze Therapeutics Inc   17.90 $ 411.087  Millions$ 22.961  Millions
Crispr Therapeutics Ag  17.79 $ 2,364.352  Millions$ 132.896  Millions
Taysha Gene Therapies Inc   17.53 $ 455.407  Millions$ 25.975  Millions
Aura Biosciences Inc   16.56 $ 323.840  Millions$ 19.560  Millions
Kalaris Therapeutics Inc   16.46 $ 143.865  Millions$ 8.738  Millions
Kyverna Therapeutics Inc   16.10 $ 367.021  Millions$ 22.802  Millions
Tectonic Therapeutic Inc   15.96 $ 227.068  Millions$ 14.224  Millions
Candel Therapeutics Inc   15.89 $ 201.565  Millions$ 12.685  Millions
Inhibikase Therapeutics Inc   15.50 $ 159.019  Millions$ 10.260  Millions
Voyager Therapeutics Inc   13.75 $ 229.369  Millions$ 16.685  Millions
Leonabio Inc   13.07 $ 102.167  Millions$ 7.817  Millions
Lenz Therapeutics Inc   12.82 $ 220.651  Millions$ 17.212  Millions
X4 Pharmaceuticals Inc  11.41 $ 220.874  Millions$ 19.366  Millions
Quince Therapeutics Inc   11.30 $ 116.000  Millions$ 10.262  Millions
Compass Therapeutics Inc   11.15 $ 179.879  Millions$ 16.128  Millions
Odyssey Therapeutics, Inc.  10.98 $ 310.575  Millions$ 28.295  Millions
Protara Therapeutics Inc  10.70 $ 142.494  Millions$ 13.319  Millions
Engene Therapeutics Inc   9.79 $ 266.320  Millions$ 27.209  Millions
Eikon Therapeutics Inc   9.61 $ 531.178  Millions$ 55.296  Millions
Zura Bio Limited  9.46 $ 205.134  Millions$ 21.690  Millions
4d Molecular Therapeutics Inc   9.16 $ 436.624  Millions$ 47.673  Millions
Fate Therapeutics Inc   8.44 $ 275.141  Millions$ 32.592  Millions
Monte Rosa Therapeutics Inc   8.32 $ 1,152.100  Millions$ 138.548  Millions
Cullinan Therapeutics Inc   8.23 $ 334.500  Millions$ 40.628  Millions
Prokidney Corp   7.99 $ 181.564  Millions$ 22.710  Millions
In8bio Inc   7.97 $ 17.956  Millions$ 2.254  Millions
Denali Therapeutics Inc   7.89 $ 710.471  Millions$ 90.083  Millions

Date modified: 2026-08-18T07:46:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.